What You Should Know:
–AiCure launches digital biomarker platform to remotely detect subtle changes in a patient’s condition, leverages computer vision and AI to gather and analyze visual and auditory cues directly through the patient’s smartphone camera.
–AiCure appoints Ed Ikeguchi, M.D. as its Chief Executive Officer (CEO) to advance AiCure’s commitment to improving holistic health through an understanding of the science behind human responses to illness and treatment.
AiCure, an AI and advanced data analytics company focused on improving clinical trials, today introduced to the market its digital biomarker platform to remotely detect subtle changes in a patient’s condition. The platform leverages computer vision andAIto gather and analyze visual and auditory cues directly through the patient’s smartphone camera, pinpointing critical patient responses and behavioral trends with the frequency and accuracy needed to elevate the integrity of clinical trial data. By aggregating clinically-sound insights in a patient’s natural environment, AiCure empowers pharmaceutical companies to improve their understanding of disease symptomology, drug dosing side effects, and stratified disease variations, ultimately supporting improved health and trial outcomes.
Eliminating Blind Spots
In any clinical trial, the collection of accurate data of a patient’s response to treatment is critical to understanding the impact a drug actually has on patients. Often, clinical trials require several in-person patient visits where clinicians note any changes in a person’s emotional and physical condition. These visits, which can be burdensome for patients and expensive for trial sponsors, can be infrequent and subjective, especially as patient symptoms may not be visible at the time of the visit. AiCure aims to eliminate these blind spots by creating more frequent check-ins that take place in the comfort of a patient’s home, providing more accurate accounts of a patient’s holistic wellbeing. AiCure’s digital biomarker platform uses a person’s smartphone to ask the patient simple questions or have them complete brief tasks, and then uses AI to analyze behavior, such as response time, affect, physical movement and speech patterns.
例如，许多神经系统疾病都有明显的视觉症状适应症。Aicure的平台可用于测量帕金森氏病患者的面部震颤或眼睛抽搐的严重程度。对患者对治疗的反应的这种高度敏感的测量可以提高试验数据的有效性，并提出有关药物影响的索赔。
Building on the success of its medication adherence platform, AiCure’s digital biomarker platform:
通过智能手机捕获视觉和音频数据 - AICURE的数字生物标志物的投资组合比传统的可穿戴指标（例如运动趋势）的测量要多得多。取而代之的是，它通过同时跟踪各种指标（包括情绪，震颤或认知）来帮助推进数字生物标志行业，以表明对治疗的负面反应。通过通过智能手机等日常设备这样做，该平台有助于使访问和参与的民主化，并提高持续参与的可能性。
Complies with data privacy regulations– The platform offers objective observations of patients and clinical trial participants in their natural environment, while providing HIPAA and GDPR compliant patient data. This allows for medical-grade, secure data capture and processing.
Developed to be scientifically sound and open– AiCure has developed its platform to be transparent and gives pharmaceutical companies open access to its algorithms’ methodologies. Built on validated scientific methodologies in laboratory-based settings, AiCure’s digital biomarker algorithms provide meaningful, clinically sound data that can be submitted to the FDA.
AiCure Appoints Former Medidata Founder Ed Ikeguchi as CEO
除了平台公告外，该公司还宣布了M.D. Ed Ikeguchi，担任首席执行官（CEO）。Ikeguchi博士以前担任公司首席医疗官（CMO）和总裁，任命首席执行官将通过了解人类对疾病和治疗的反应背后的科学来提高AICURE对改善整体健康的承诺。随着今天宣布数字生物标志物的消息，AICURE正在以这种愿景为基础。
在2018年加入AICURE的CMO之前，Ikeguchi博士共同创立了Medidata Solutions，在那里他从成立到2009年的首次公开募股，同时从1999年至2001年担任首席执行官，并从2001-2009担任CMO。Ikeguchi博士在C-Suite和临床环境中的丰富经验，包括他对患者参与的许多痛苦点的理解，使他在下一阶段处于领先地位。
